Maxim Group reiterated their buy rating on shares of Fennec Pharmaceuticals (TSE:FRX – Get Rating) in a report released on Thursday, TipRanks reports. Maxim Group currently has a C$10.00 price target on the biopharmaceutical company’s stock. Separately, Cantor Fitzgerald downgraded Fennec Pharmaceuticals from an overweight rating to a neutral rating in a report on Tuesday, […]